The Kissing Booth 3

Axiom Exhibiting at Outsourcing in Clinical Trials Southern California 2022

Retrieved on: 
Tuesday, September 27, 2022
Metric, Clinical data management, Coffee, EDC, Booth, Sample and Data Relationship Format, Service, Patient, EPRO, CEO, The Kissing Booth 3, Axiom, Data management, Solution, CA, CTMS, Patient portal, Clinical trial, Single sign-on, GLOBE, DM, Fine chemical, Pharmaceutical industry, Pharmacovigilance, Biostatistics

TORONTO, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Axiom Real-Time Metrics ("Axiom"), a premier provider of unified eClinical solutions and services focused on small-to-medium life science organizations, will be exhibiting at Outsourcing in Clinical Trials Southern California 2022, September 28-29 in San Diego, CA.

Key Points: 
  • TORONTO, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Axiom Real-Time Metrics ("Axiom"), a premier provider of unified eClinical solutions and services focused on small-to-medium life science organizations, will be exhibiting at Outsourcing in Clinical Trials Southern California 2022, September 28-29 in San Diego, CA.
  • For this years program, delegates can attend two different streams: Clinical Operations & Outsourcing and Clinical Technology & Innovation.
  • The conference will bring together pharmaceutical and biotech experts to connect and explore solutions to current challenges associated with clinical trials.
  • Axiom invites attendees to come visit the team at Booth 3 for a chat over coffee to discuss upcoming needs and how Axiom can help run your clinical trials easier, faster, and smarter.

Applied DNA Biotherapeutics Subsidiary LineaRx to Present Data Showcasing Advantages of its Enzymatically Produced LinearDNA as Substitute for Plasmid DNA in IVT mRNA Production at the 2nd Annual mRNA-Based Therapeutics Summit

Retrieved on: 
Friday, July 22, 2022
Science, Other Science, Biometrics, Biotechnology, Research, Pharmaceutical, Health, Genetics, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, DNA, The Kissing Booth 3, IVT, Twitter, Applied DNA Sciences, Food, Polymerase chain reaction, Booth, CEO, Forward-looking statement, SEC, History, Research, Securities Act of 1933, Private Securities Litigation Reform Act, Securities Exchange Act of 1934, RNA transfection, NASDAQ, United States Department of State, Leadership, Biotechnology, USDA, FDA, Plasmid, LinkedIn, Therapy, Annual report, Summit, Drug Quality and Security Act, United States Department of Agriculture, PCR, Workflow, RNA, Vaccine, Applied Food Technologies

A copy of the slide presentation will be made available to interested parties concurrent with the start of the presentation at https://linearxdna.com/ .

Key Points: 
  • A copy of the slide presentation will be made available to interested parties concurrent with the start of the presentation at https://linearxdna.com/ .
  • linDNA is an optimal IVT template for mRNA production as compared to plasmid DNA (pDNA).
  • Current IVT mRNA production methods must improve to move mRNA technology to broader commercialization to support therapeutic and vaccine development.
  • Applied DNA Sciences is a biotechnology company developing technologies to produce and detect deoxyribonucleic acid ("DNA").